Blocking TYRO3 signaling by human anti-TYRO3 antibody ameliorates cancer malignancy and increased sensitivity to paclitaxel, oxaliplatin and 5-fluorouracil in different colon cancer cell lines (Chien et al. 2016). This evidence concerns the gene TYRO3 and malignant colon neoplasm.